| Chelsea Whitmire, MA, CCC-SLP | |
|
807b Magnolia Dr, Aberdeen, NC 28315-2205 | |
| (419) 889-0435 | |
| Not Available |
| Full Name | Chelsea Whitmire |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 807b Magnolia Dr, Aberdeen, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558719120 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | LL60641307 (Washington) | Primary |
| Provider Name | Paragon Outpatient Rehabilitation Services, Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1871867325 PECOS PAC ID: 8022272848 Enrollment ID: O20160728001716 |
News Archive
Maintaining positive, warm and trusting friendships might be the key to a slower decline in memory and cognitive functioning, according to a new Northwestern Medicine study.
The Wall Street Journal: "Indian technology companies are eyeing a coming wave of U.S. spending to digitize health care records. But sensitivity over outsourcing and resistance by American hospitals to sending medical information overseas could thwart efforts to win big contracts." Next year, the U.S. government will dispense billions to "health-care providers who adopt electronic medical records." Doctors are also facing "a federal mandate to upgrade software as the U.S. switches to a new system of insurance billing codes."
Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approved NINLARO (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.
More involvement by patients, clinicians and others in the health care community in developing comparative clinical effectiveness research studies will make such studies far more useful in clinical decision-making, according to the Patient-Centered Outcomes Research Institute, in an article published in the April 18 issue of JAMA, a theme issue on comparative effectiveness research.
› Verified 1 days ago
| Provider Name | Aegis Group Practice Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093389751 PECOS PAC ID: 5193036432 Enrollment ID: O20210621000546 |
News Archive
Maintaining positive, warm and trusting friendships might be the key to a slower decline in memory and cognitive functioning, according to a new Northwestern Medicine study.
The Wall Street Journal: "Indian technology companies are eyeing a coming wave of U.S. spending to digitize health care records. But sensitivity over outsourcing and resistance by American hospitals to sending medical information overseas could thwart efforts to win big contracts." Next year, the U.S. government will dispense billions to "health-care providers who adopt electronic medical records." Doctors are also facing "a federal mandate to upgrade software as the U.S. switches to a new system of insurance billing codes."
Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approved NINLARO (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.
More involvement by patients, clinicians and others in the health care community in developing comparative clinical effectiveness research studies will make such studies far more useful in clinical decision-making, according to the Patient-Centered Outcomes Research Institute, in an article published in the April 18 issue of JAMA, a theme issue on comparative effectiveness research.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chelsea Whitmire, MA, CCC-SLP 807b Magnolia Dr, Aberdeen, NC 28315-2205 Ph: (419) 889-0435 | Chelsea Whitmire, MA, CCC-SLP 807b Magnolia Dr, Aberdeen, NC 28315-2205 Ph: (419) 889-0435 |
News Archive
Maintaining positive, warm and trusting friendships might be the key to a slower decline in memory and cognitive functioning, according to a new Northwestern Medicine study.
The Wall Street Journal: "Indian technology companies are eyeing a coming wave of U.S. spending to digitize health care records. But sensitivity over outsourcing and resistance by American hospitals to sending medical information overseas could thwart efforts to win big contracts." Next year, the U.S. government will dispense billions to "health-care providers who adopt electronic medical records." Doctors are also facing "a federal mandate to upgrade software as the U.S. switches to a new system of insurance billing codes."
Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approved NINLARO (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.
More involvement by patients, clinicians and others in the health care community in developing comparative clinical effectiveness research studies will make such studies far more useful in clinical decision-making, according to the Patient-Centered Outcomes Research Institute, in an article published in the April 18 issue of JAMA, a theme issue on comparative effectiveness research.
› Verified 1 days ago